Journal ArticleDOI
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
William E. Klunk,Henry Engler,Agneta Nordberg,Yanming Wang,G. Blomqvist,Daniel P. Holt,Mats Bergström,Irina Savitcheva,Guo Feng Huang,Sergio Estrada,Birgitta Ausén,Manik L. Debnath,Julien Barletta,Julie C. Price,Johan Sandell,Brian J. Lopresti,Anders Wall,Pernilla Koivisto,Gunnar Antoni,Chester A. Mathis,Bengt Långström +20 more
Reads0
Chats0
TLDR
The results suggest that PET imaging with the novel tracer, PIB, can provide quantitative information on amyloid deposits in living subjects.Abstract:
This report describes the first human study of a novel amyloid-imaging positron emission tomography (PET) tracer, termed Pittsburgh Compound-B (PIB), in 16 patients with diagnosed mild AD and 9 controls. Compared with controls, AD patients typically showed marked retention of PIB in areas of association cortex known to contain large amounts of amyloid deposits in AD. In the AD patient group, PIB retention was increased most prominently in frontal cortex (1.94-fold, p = 0.0001). Large increases also were observed in parietal (1.71-fold, p = 0.0002), temporal (1.52-fold, p = 0.002), and occipital (1.54-fold, p = 0.002) cortex and the striatum (1.76-fold, p = 0.0001). PIB retention was equivalent in AD patients and controls in areas known to be relatively unaffected by amyloid deposition (such as subcortical white matter, pons, and cerebellum). Studies in three young (21 years) and six older healthy controls (69.5 +/- 11 years) showed low PIB retention in cortical areas and no significant group differences between young and older controls. In cortical areas, PIB retention correlated inversely with cerebral glucose metabolism determined with 18F-fluorodeoxyglucose. This relationship was most robust in the parietal cortex (r = -0.72; p = 0.0001). The results suggest that PET imaging with the novel tracer, PIB, can provide quantitative information on amyloid deposits in living subjects.read more
Citations
More filters
Journal ArticleDOI
Impact of amyloid imaging on drug development in Alzheimer's disease.
TL;DR: The ability to quantify regional Abeta plaque load in the brains of living human subjects has provided a means to begin to apply this technology as a diagnostic agent to detect regional concentrations of Abeta plaques and as a surrogate marker of therapeutic efficacy in anti-amyloid drug trials.
Journal ArticleDOI
Biomarkers for the Early Detection and Progression of Alzheimer’s Disease
Scott E. Counts,Scott E. Counts,Milos D. Ikonomovic,Natosha M. Mercado,Irving E. Vega,Elliott J. Mufson +5 more
TL;DR: The ultimate AD biomarker panel will likely involve the inclusion of novel CSF and blood biomarkers more precisely associated with confirmed pathophysiologic mechanisms to improve its reliability for detecting preclinical AD.
Journal ArticleDOI
Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia
Paula T. Trzepacz,Paula T. Trzepacz,Peng Yu,Jia Sun,Kory Schuh,Michael Case,Michael M. Witte,Helen Hochstetler,Ann Marie Hake +8 more
TL;DR: Multivariate modeling found that among individual modalities, MRI had the highest predictive accuracy, which increased by 9% to 76% when combined with PIB-PET, producing the highest accuracy among any biomarker combination.
Journal ArticleDOI
Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort.
Marissa D. Zwan,Argonde C. van Harten,Rik Ossenkoppele,Femke H. Bouwman,Charlotte E. Teunissen,Sofie Adriaanse,Adriaan A. Lammertsma,Philip Scheltens,Bart N.M. van Berckel,Wiesje M. van der Flier +9 more
TL;DR: In this paper, concordance between CSF biomarkers and positron emission tomography (PET) was investigated in a memory clinic cohort with 64 AD patients, 34 non-AD dementia patients, 22 patients with mild cognitive impairment (MCI), and 16 controls.
Journal ArticleDOI
Frontotemporal Lobar Degeneration
TL;DR: In this paper, a spectrum of clinically, pathologically and genetically heterogeneous neurodegenerative disorders of unknown aetiology is described, which can be differentiated clinically into three frontotemporal dementia (FTD) syndromes: behavioural variant (bvFTD), semantic dementia (SD), and progressive nonfluent aphasia (PNFA).
References
More filters
Journal ArticleDOI
Clinical diagnosis of Alzheimer's disease : report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
Guy M. McKhann,David A. Drachman,Marshall F. Folstein,Robert Katzman,Donald L. Price,Emanuel M. Stadlan +5 more
TL;DR: The criteria proposed are intended to serve as a guide for the diagnosis of probable, possible, and definite Alzheimer's disease; these criteria will be revised as more definitive information becomes available.
Journal ArticleDOI
Neuropathological stageing of Alzheimer-related changes.
Heiko Braak,Eva Braak +1 more
TL;DR: The investigation showed that recognition of the six stages required qualitative evaluation of only a few key preparations, permitting the differentiation of six stages.
Journal ArticleDOI
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data:
TL;DR: A theoretical model of blood–brain exchange is developed and a procedure is derived that can be used for graphing multiple-time tissue uptake data and determining whether a unidirectional transfer process was dominant during part or all of the experimental period.
Journal ArticleDOI
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
TL;DR: Aβ-deposition in the entire brain follows a distinct sequence in which the regions are hierarchically involved and expands anterogradely into regions that receive neuronal projections from regions already exhibiting Aβ.
Journal ArticleDOI
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations:
TL;DR: General equations are derived that can be used to analyze tissue uptake data when the blood–plasma concentration of the test substance cannot be easily measured and for situations when trapping of theTest substance is incomplete and for a combination of these two conditions.
Related Papers (5)
The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann,Guy M. McKhann,David S. Knopman,Howard Chertkow,Bradley T. Hyman,Clifford R. Jack,Claudia H. Kawas,William E. Klunk,Walter J. Koroshetz,Jennifer J. Manly,Richard Mayeux,Richard C. Mohs,John C. Morris,Martin N. Rossor,Philip Scheltens,Maria C. Carrillo,Bill Thies,Sandra Weintraub,Creighton H. Phelps +18 more